Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic-Reference-Cited by-同舟云学术

Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic

Published:2012-05 Issue:5 Volume:129 Page:e233-e237
ISSN:0049-3848
Container-title:Thrombosis Research
language:en
Short-container-title:Thrombosis Research

Author:

Salaj Peter,Penka Miroslav,Smejkal Petr,Geierova Vera,Ovesná Petra,Brabec Petr,Cetkovsky Petr,Kubes Radovan,Mesterton Johan,Lindgren Peter

Publisher

Elsevier BV

Subject

Hematology

Reference19 articles.

1. FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre;Smejkal;Haemophilia,2009

2. Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors;Knight;Adv Ther,2009

3. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression;Treur;Haemophilia,2009

4. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor to moderate bleeds in hemophilia patients with inhibitors;Joshi;Curr Med Res Opin,2006

5. A cost evaluation of treatment alternatives for mild to moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil;Ozelo;Haemophilia,2007

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality;Expert Review of Hematology;2020-01-22

2. Cost-Effectiveness of rFVIIa versus pd-aPCC in the Management of Mild to Moderate Bleeds in Pediatric Patients with Hemophilia A with Inhibitors in Mexico;Value in Health Regional Issues;2018-12

3. The socioeconomic burden of patients affected by hemophilia with inhibitors;European Journal of Haematology;2018-07-27

4. Inhibitors in Hemophilia A: A Pharmacoeconomic Perspective;Seminars in Thrombosis and Hemostasis;2017-12-08

5. Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions;PharmacoEconomics;2017-11-23